ResMed (NYSE: RMD) is a very interesting company. It develops medical equipment that you can use yourself at home to treat a breathing disorder that occurs during sleep. This disease, called SDB, results from obesity, sleep apnea, diabetes, and cardiovascular diseases, and in turn, causes or enhances a few of them, for example, heart problems and diabetes. So, in effect, treating SDB also assists in treating these other diseases, thereby more »
In the previous section of this article, I discussed ResMed (NYSE: RMD) and its excellent market position, how well it has been paying dividends (almost always an indication of a mature company), and how its technology is being utilized to treat new indications. In this section, I will conclude with a look at its global growth, and its competitors.
Product Sales Driving Growth Across Geographies for ResMed
One of the more »
An aging western society has opened many opportunities for firms involved in pharmaceuticals, medical instruments and supplies. The following three: ResMed (NYSE: RMD), Covidien (NYSE: COV), and Baxter International (NYSE: BAX) have created a small economic moats for themselves, are fair valued, and hold positive future outlooks. Let us find why, despite their troubled present, their futures may be brighter.
Already dreaming more profits
Focused on sleep disorders, medical instruments more »
ResMed (NYSE: RMD), the Australian-based global developer, manufacturer, and distributor of medical devices is showing success to investors by not only beating EPS expectations and disclosing its 71st consecutive quarter of revenue growth, but also, and most importantly, by showing the re-establishment of its position as the leading company in the sleep apnea treatment industry in the United States.
The company in a snapshot.
a) Its third quarter report more »
ResMed (NYSE: RMD) has been a stock of interest in the community of bivio investment clubs during the past couple of years. Clubs are always looking for good, small-company stocks whose higher potential growth rates might help them beat the returns of the overall market. They've been attracted by the historical sales growth rate of ResMed, which has averaged an attractive 15.5% over the past 5 years. In more »
By Brandy Betz - January 8, 2012 | Tickers: ARAY, ACOR, A, ALGN, AMRN, AMGN, AMLN, ARTC, BIIB, BMRN, BRKR, CFN, CTRX, CELG, CNC, COV, DNDN, XRAY, EW, ENDP, EPOC, ESRX, GHDX, GILD, HLS, HTWR, HMSY, HGSI, IDXX, IPXL, INCY, IRWD, MCK, MRX, MDT, MR, MOH, MYL, NVS, ONXX, PRX, PRGO, QSII, REGN, RMD, RIGL, SGEN, ST, SIAL, THC, MDCO, THOR, VRTX, VVUS, WAT, WMGI, ZLTQ
The 30th Annual J.P. Morgan Healthcare Conference kicks off with a full day of presentations from companies that range from global pharmaceutical leaders to small cap novel pharmaceutical developers and health technology manufacturers. The majority of the presentations will be available through live webcasts with archived replay offered later in the day.